Jefferies Assumes Viridian Therapeutic (VRDN) at Buy

Jefferies analyst Kelly Shi assumes coverage on Viridian Therapeutic (NASDAQ: VRDN) with a Buy rating and a price target of $44.00.

The analyst comments "VRDN is an attractive late-stage story trading at ~$1.5B with veligrotug ready to file for multi-$B thyroid eye disease (TED) market. While veli has initial differentiation vs Tepezza (FY24 ~$2B rev) with streamlined 5-dose IV + rapid onset, we think VDRN-003 (SubQ) could be a game changer to double chronic TED market with convenience + pot'l better safety. Early FcRn pipeline may drive longer-term growth w/ proven MoA. Transferring lead coverage to Kelly Shi."

For an analyst ratings summary and ratings history on Viridian Therapeutic click here. For more ratings news on Viridian Therapeutic click here.

Shares of Viridian Therapeutic closed at $18.02 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Mosaic sets pricing for tender offers on up to $1.4B in debt